Session Information
Date: Sunday, November 5, 2017
Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose:
Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this study was to investigate the safety of bisphosphonates on renal function in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures after vertebroplasty.
Methods:
This retrospective study enrolled patients with osteoporosis and acute vertebral fractures who underwent vertebroplasty between January 2001 and December 2015. Their gender, age, body mass index, co-morbidities, and use of zoledronic acid were recorded. The patients with increased creatinine were defined as having worse renal function. Logistic regression was used to adjust for variables.
Results:
Of the 224 included patients (184 females; mean age, 72.91±9.26 years), 82 took zoledronic acid and the others received other anti-osteoporotic agents. Fifty-four (65.9%) of the patients who took zoledronic acid had an increased creatinine level, compared to 92 (64.8%) of those who received other anti-osteoporotic agents (p=0.885). After adjusting for confounding variables, zoledronic acid was not significantly associated with an increase in creatinine (p=0.815; OR: 0.926; 95% CI: 0.487-1.761).
Conclusion:
The use of zoledronic acid did not lead to an increase in creatinine compared to those who used did not use zoledronic acid. However, further studies are needed to confirm our findings.
|
Table . Risk of zoledronic acid treatment increasing creatinine after adjustments for covariates |
||||||
|
Regression coefficient |
SE |
P value |
OR(95CI) |
|||
|
Zoledronic acid |
-0.076 |
0.328 |
0.815 |
0.926(0.487-1.761) |
||
|
Age |
0.057 |
0.023 |
0.012 |
1.059(1.013-1.107) |
||
|
BMI |
-0.023 |
0.034 |
0.499 |
0.977(0.914-1.045) |
||
|
Gender |
0.281 |
0.469 |
0.548 |
1.324(0.529-3.321) |
||
|
Smoking |
-0.867 |
0.859 |
0.313 |
0.420(0.078-2.263) |
||
|
Alcohol consumption |
1.577 |
1.116 |
0.158 |
4.838(0.543-43.150) |
||
|
Diabetes |
-0.324 |
0.334 |
0.333 |
0.723(0.376-1.393) |
||
|
Hypertension |
0.285 |
0.317 |
0.369 |
1.329(0.715-2.473) |
||
|
Neurologic disease |
-1.235 |
0.499 |
0.013 |
0.290(0.109-0.773) |
||
|
Cardiovascular disease |
-0.091 |
0.430 |
0.832 |
0.913(0.393-2.120) |
||
|
Pulmonary disease |
0.147 |
0.399 |
0.713 |
1.158(0.530-2.532) |
||
|
Gastrointestinal disease |
-0.351 |
0.363 |
0.334 |
0.703(0.345-1.435) |
||
|
Liver disease |
0.524 |
0.465 |
0.260 |
1.688(0.679-4.201) |
||
|
Renal disease |
0.930 |
0.435 |
0.033 |
2.534(1.080-5.950) |
||
|
Key: CI: confidence interval; OR: odds ratio; SE: standard error; BMI: body mass index |
||||||
To cite this abstract in AMA style:
Chen YC Sr.. Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/zoledronic-acid-did-not-impaired-renal-function-in-patients-with-osteoporosis/. Accessed .« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/zoledronic-acid-did-not-impaired-renal-function-in-patients-with-osteoporosis/